Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hants Brandon

(Last)

(First)

(Middle)

C/O APPLIED MOLECULAR TRANSPORT INC.

1209 ORANGE STREET

(Street)

WILMINGTON

19801

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Applied Molecular Transport Inc. [ AMTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
CFO

3. Date of Earliest Transaction (Month/Day/Year)
12/27/2023

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	12/27/2023		D		301,225	D	⁽¹⁾⁽²⁾	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$2.38	12/27/2023		D			150,672	⁽³⁾	03/26/2029	Common Stock	150,672	$0.00	0	D
Stock Option (Right to Buy)	$4.61	12/27/2023		D			4,328	⁽³⁾	03/30/2030	Common Stock	4,328	$0.00	0	D
Stock Option (Right to Buy)	$14	12/27/2023		D			20,000	⁽³⁾	06/04/2030	Common Stock	20,000	$0.00	0	D
Stock Option (Right to Buy)	$56.61	12/27/2023		D			76,000	⁽³⁾	03/01/2031	Common Stock	76,000	$0.00	0	D
Stock Option (Right to Buy)	$8.29	12/27/2023		D			57,400	⁽³⁾	02/15/2032	Common Stock	57,400	$0.00	0	D
Stock Option (RIght to Buy)	$3.99	12/27/2023		D			35,000	⁽³⁾	05/16/2032	Common Stock	35,000	$0.00	0	D
Stock Option (Right to Buy)	$0.3639	12/27/2023		D			50,000	⁽⁴⁾	12/26/2033	Common Stock	50,000	$0.00	0	D

Explanation of Responses:

1. Pursuant to the Agreement and Plan of Merger dated as of September 21, 2023 (the "Merger Agreement"), by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc. and the Issuer, each share of Issuer's Common Stock was converted into 0.1331 of a share of Cyclo Common Stock (the "Transaction Consideration").

2. Upon consummation of the Merger, the Reporting Person received Transaction Consideration of 40,094 shares of Cyclo common stock.

3. Pursuant to the Merger Agreement, at the effective time of the merger, each outstanding option with an exercise price of $0.40 or more was cancelled effective as of the closing.

4. Pursuant to the Merger Agreement, this option was exchanged for an option covering 6,655 shares of Cyclo Common Stock.

Remarks:

	/s/ Brandon Hants	12/28/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.